Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+MPN Cells

被引：0
|
作者：
Keller, Alexandra [1 ,2 ]
Peter, Barbara [1 ,2 ]
Zuber, Johannes [3 ]
Staber, Philipp Bernhard [2 ]
Bettelheim, Peter [4 ]
Valent, Peter [1 ,2 ]
Hadzijusufovic, Emir [1 ,2 ,5 ]
机构：
[1] Med Univ Vienna, Ludwig Boltzmann Cluster Oncol, Vienna, Austria
[2] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Vienna, Austria
[3] Res Inst Mol Pathol IMP, Vienna, Austria
[4] Elisabethinen Hosp, Dept Med 1, Linz, Austria
[5] Univ Vet Med Vienna, Internal Med, Small Anim Clin, Dept Compan Anim & Horses, Vienna, Austria
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway
    Ly Quoc Trung
    Espinoza, J. Luis
    An, Dao T.
    Nguyen Hoang Viet
    Shimoda, Kazuya
    Nakao, Shinji
    MOLECULAR NUTRITION & FOOD RESEARCH, 2015, 59 (11) : 2143 - 2154
  • [42] Estimation of JAK2 V617F Prevalence by Detection of the Mutation in Saliva Samples From Online MPN and General Population Cohorts
    Barnholt, Kimberly E.
    Hinds, David A.
    Kiefer, Amy K.
    Do, Chuong B.
    Eriksson, Nicholas
    Mountain, Joanna L.
    Francke, Uta
    Tung, Joyce A.
    Nguyen, Huong
    Levine, Ross L.
    Mesa, Ruben A.
    Gotlib, Jason
    Zehnder, James L.
    BLOOD, 2012, 120 (21)
  • [43] JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics
    McKerrell, Thomas
    Park, Naomi
    Chi, Jianxiang
    Collord, Grace
    Moreno, Thaidy
    Ponstingl, Hannes
    Dias, Joao M. L.
    Gerasimou, Petroula
    Melanthiou, Kiki
    Prokopiou, Chrystalla
    Antoniades, Marios
    Varela, Ignacio
    Costeas, Paul A.
    Vassiliou, George S.
    BLOOD ADVANCES, 2017, 1 (14) : 968 - 971
  • [44] Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN)
    Zulkeflee, Razan Hayati
    Zulkafli, Zefarina
    Johan, Muhammad Farid
    Husin, Azlan
    Islam, Md Asiful
    Hassan, Rosline
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (14)
  • [45] EXPRESSION OF PSTAT5 IN CD34+/CD38-STEM CELLS IN JAK2 V617F+MYELOPROLIFERATIVE NEOPLASMS (MPN)
    Hadzijusufovic, E.
    Schur, F.
    Cerny-Reiterer, S.
    Pecnard, E.
    Gouilleux, F.
    Valent, P.
    HAEMATOLOGICA, 2012, 97 : 45 - 45
  • [46] Myelodysplastic syndromes with myelofibrosis may be a target for the JAK2 V617F tyrosine kinase mutation.
    Ohyashiki, K
    Aota, Y
    Gotoh, A
    Miyazawa, K
    Kimura, Y
    Ohyashiki, JH
    BLOOD, 2005, 106 (11) : 304B - 304B
  • [47] Hypoxia Blocks Activation of JAK2V617F Through Suppression of SHP-2 Expression in MPN Cells
    Mitsumori, Toru
    Nozaki, Yumi
    Komatsu, Norio
    Kirito, Keita
    BLOOD, 2011, 118 (21) : 61 - 61
  • [48] Effects of Ruxolitinib on Immune Checkpoint Molecule Expression in JAK2 V617F-Positive Cells
    Fu, Jianzhu
    Cheng, Zhiyong
    Zhang, Lijun
    Wen, Xingchu
    Hao, Jianxue
    CLINICAL LABORATORY, 2024, 70 (10) : 1897 - 1907
  • [49] TUMOR NECROSIS FACTOR RECEPTOR 2 MAY BE REQUIRED FOR CLONAL DOMINANCE OF JAK2 V617F MUTANT OVER JAK2 WILDTYPE CELLS
    Deininger, M.
    Heaton, W.
    Senina, A.
    Pomicter, A.
    Marvin, J.
    Swierczek, S.
    Eiring, A.
    Prchal, J.
    O'Hare, T.
    HAEMATOLOGICA, 2016, 101 : 188 - 189
  • [50] Features of immune mediated diseases in JAK2 (V617F)-positive myeloproliferative neoplasms and the potential therapeutic role of JAK inhibitors
    Alvarez-Reguera, Carmen
    Prieto-Pena, Diana
    Herrero-Morant, Alba
    Sanchez-Bilbao, Lara
    Batlle-Lopez, Ana
    Fernandez-Luis, Sara
    Paz-Gandiaga, Nerea
    Blanco, Ricardo
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 123 : 102 - 106
12345